JP2021522296A5 - - Google Patents

Info

Publication number
JP2021522296A5
JP2021522296A5 JP2020561032A JP2020561032A JP2021522296A5 JP 2021522296 A5 JP2021522296 A5 JP 2021522296A5 JP 2020561032 A JP2020561032 A JP 2020561032A JP 2020561032 A JP2020561032 A JP 2020561032A JP 2021522296 A5 JP2021522296 A5 JP 2021522296A5
Authority
JP
Japan
Prior art keywords
compound
salt
cells
vaccination
immunostimulant
Prior art date
Application number
JP2020561032A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019211294A5 (https=
JP7557374B2 (ja
JP2021522296A (ja
Filing date
Publication date
Priority claimed from GBGB1807051.6A external-priority patent/GB201807051D0/en
Priority claimed from GBGB1807819.6A external-priority patent/GB201807819D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/061093 external-priority patent/WO2019211294A1/en
Publication of JP2021522296A publication Critical patent/JP2021522296A/ja
Publication of JPWO2019211294A5 publication Critical patent/JPWO2019211294A5/ja
Publication of JP2021522296A5 publication Critical patent/JP2021522296A5/ja
Priority to JP2024159173A priority Critical patent/JP2024170634A/ja
Application granted granted Critical
Publication of JP7557374B2 publication Critical patent/JP7557374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561032A 2018-04-30 2019-04-30 免疫増強剤としてのウロリチンａ Active JP7557374B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024159173A JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1807051.6A GB201807051D0 (en) 2018-04-30 2018-04-30 Biological enhancer
GB1807051.6 2018-04-30
GB1807819.6 2018-05-14
GBGB1807819.6A GB201807819D0 (en) 2018-05-14 2018-05-14 Biological enhancer
PCT/EP2019/061093 WO2019211294A1 (en) 2018-04-30 2019-04-30 Urolithin a as immune enhancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024159173A Division JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Publications (4)

Publication Number Publication Date
JP2021522296A JP2021522296A (ja) 2021-08-30
JPWO2019211294A5 JPWO2019211294A5 (https=) 2022-05-13
JP2021522296A5 true JP2021522296A5 (https=) 2022-05-13
JP7557374B2 JP7557374B2 (ja) 2024-09-27

Family

ID=66379918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561032A Active JP7557374B2 (ja) 2018-04-30 2019-04-30 免疫増強剤としてのウロリチンａ
JP2024159173A Pending JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024159173A Pending JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Country Status (7)

Country Link
US (3) US10792276B2 (https=)
EP (1) EP3787615A1 (https=)
JP (2) JP7557374B2 (https=)
CN (1) CN112512517A (https=)
BR (1) BR112020022159A2 (https=)
MX (2) MX2020011619A (https=)
WO (1) WO2019211294A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer
WO2020148445A1 (en) * 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
US20240000747A1 (en) * 2020-11-26 2024-01-04 Daicel Corporation Sirtuin 6 activator
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
JP2024516187A (ja) * 2021-05-05 2024-04-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるためのウロリチン
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN117180267B (zh) * 2023-10-25 2026-03-13 深圳市第三人民医院(深圳市肝病研究所) 一种尿石素a在制备药物中的应用及药物
WO2025224366A1 (en) * 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127263A2 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
DK4233858T3 (da) * 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
EP3663287B1 (en) 2013-12-23 2023-09-20 Amazentis SA Process scale synthesis of urolithins
WO2016099947A1 (en) * 2014-12-19 2016-06-23 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
US20170304263A1 (en) * 2016-04-20 2017-10-26 John Michael Pezzuto Antioxidative stress compositions, methods of preparing and uses thereof
WO2019163437A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer

Similar Documents

Publication Publication Date Title
JP2021522296A5 (https=)
Garçon et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach
Cunningham et al. Vaccine development: From concept to early clinical testing
Cimica et al. Adjuvant formulations for virus-like particle (VLP) based vaccines
Altenburg et al. Virus-specific T cells as correlate of (cross-) protective immunity against influenza
JP2017523180A5 (https=)
JP2021534183A5 (https=)
TW200722101A (en) Novel composition
JPWO2019211294A5 (https=)
JP2011504486A5 (https=)
JP2009539965A5 (https=)
MX2007008010A (es) Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
JP2021505648A5 (https=)
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
CA3010049C (en) Vaccine containing immobilized virus particles
JP2016502996A (ja) ナイーブな対象のためのワクチン組成物
JP2011525902A (ja) 遅延型追加刺激免疫処置に対する迅速な応答
JP2024150687A (ja) アジュバントおよび該アジュバントを含むワクチン
Liu et al. A cationic liposome–DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets
Depelsenaire et al. Introduction to vaccines and vaccination
RU2016141621A (ru) Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин
Moingeon et al. Therapeutic vaccines against infectious diseases
Rehmani et al. The influence of adjuvants on oral vaccination of chickens against Newcastle disease
Modjarrad et al. Human vaccines: emerging technologies in design and development
Hay What you need to know